Clinical trial · Observational
Insights Into Participating in Studies for Bone Cancer
Examining Patient Involvement Patterns and Trends in Participation in Bone Cancer Clinical Trials
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Clinical studies, with a distinct focus on bone cancer, play a crucial role in evaluating the safety and effectiveness of novel treatments for this disease. These trials serve as instrumental means to determine whether new medications surpass conventional therapies, providing substantial evidence for their broader adoption. The primary objective is to meticulously scrutinize trial completion rates and voluntary withdrawals within this specific patient group.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bone Cancer | Malignant Bone Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Rate of patients who decide to enroll in a bone cancer clinical research.
- timeFrame
- 3 months
- measure
- Number of bone cancer study participants who remain in clinical study until completion.
- timeFrame
- 12 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Aged ≥ 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed * Diagnosis of bone cancer * No prior treatment for bone cancer Exclusion Criteria: * Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial * Enrolled in another research study * Inability to provide written informed consent
References
Publications (3)
- BACKGROUNDVentura C, Nunez SV, Goncalves A, Abreu C, Costa L. Bone Health in Metastatic Cancer. Semin Oncol Nurs. 2022 Apr;38(2):151278. doi: 10.1016/j.soncn.2022.151278. Epub 2022 Apr 15. PMID 35431084
- BACKGROUNDPorta-Sales J, Garzon-Rodriguez C, Llorens-Torrome S, Brunelli C, Pigni A, Caraceni A. Evidence on the analgesic role of bisphosphonates and denosumab in the treatment of pain due to bone metastases: A systematic review within the European Association for Palliative Care guidelines project. Palliat Med. 2017 Jan;31(1):5-25. doi: 10.1177/0269216316639793. Epub 2016 Jul 10. PMID 27006430
- BACKGROUNDNiiyama Y, Kawamata T, Yamamoto J, Furuse S, Namiki A. SB366791, a TRPV1 antagonist, potentiates analgesic effects of systemic morphine in a murine model of bone cancer pain. Br J Anaesth. 2009 Feb;102(2):251-8. doi: 10.1093/bja/aen347. Epub 2008 Nov 26. PMID 19038965